{
    "hands_on_practices": [
        {
            "introduction": "The location of blister formation in pemphigus is not random; it is dictated by the specific autoantibodies and the distribution of their target antigens in the epidermis. This exercise  brings the \"desmoglein compensation hypothesis\" to life by formalizing it into a simple biophysical model. By calculating and comparing adhesion strengths in different epithelial layers, you can predict the precise cleavage plane, a skill that mirrors the diagnostic reasoning used to distinguish between pemphigus vulgaris and pemphigus foliaceus based on histopathology.",
            "id": "4429998",
            "problem": "A pemphigus vulgaris modeling exercise asks you to formalize a two-layer stratified squamous epithelium with differential desmoglein expression and to predict the mechanical cleavage plane under antibody-mediated disruption. Use the following foundations:\n\n- Desmosomal adhesion is mediated by desmoglein isoforms, with Desmoglein (Dsg) $3$ enriched in basal layers and Desmoglein $1$ enriched superficially.\n- Mechanical failure occurs at an interface when the applied shear stress exceeds the cohesive adhesion strength at that interface.\n\nModel the tissue as two cellular layers: a basal layer and a suprabasal layer. Let the basal–suprabasal interface adhesion strength be the sum of Dsg$3$- and Dsg$1$-mediated contributions, and let the suprabasal–superficial interface (representing the interface between the suprabasal layer and the overlying differentiating cells) be dominated by Dsg$1$ with a minor Dsg$3$ contribution. Specifically, define the adhesion strengths (in arbitrary adhesion units, AAU) as\n$$\nS_{bs} \\;=\\; \\alpha_{3}\\,c_{3b}\\,c_{3s} \\;+\\; \\alpha_{1}\\,c_{1b}\\,c_{1s},\n\\qquad\nS_{ss} \\;=\\; \\beta_{1}\\,c_{1s}^{2} \\;+\\; \\beta_{3}\\,c_{3s}^{2},\n$$\nwhere $c_{3b}$ and $c_{1b}$ denote basal concentrations of Dsg$3$ and Dsg$1$, respectively, and $c_{3s}$ and $c_{1s}$ denote suprabasal concentrations. Use the parameter values\n- $c_{3b} = 8$, $c_{1b} = 2$, $c_{3s} = 2$, $c_{1s} = 8$,\n- $\\alpha_{3} = 1$, $\\alpha_{1} = 0.2$, $\\beta_{1} = 1$, $\\beta_{3} = 0.1$.\n\nAssume a uniform applied shear stress $T = 10$ (AAU). In the presence of anti-Dsg$3$ antibodies that reduce the basal–suprabasal adhesion by a fraction $0.60$, take the post-antibody basal–suprabasal strength to be\n$$\nS_{bs}^{(\\text{Ab})} \\;=\\; (1 - 0.60)\\,S_{bs}.\n$$\nAssume the suprabasal–superficial strength $S_{ss}$ is unchanged.\n\nUsing only the above definitions and the principle that failure occurs where $T$ exceeds the local $S$, determine the predicted cleavage plane as an integer code with the following convention:\n- $1$ denotes cleavage at the basal–suprabasal interface (suprabasal split),\n- $2$ denotes cleavage at the suprabasal–superficial interface (superficial split).\n\nProvide your final answer as the single integer code. No rounding is required, and no units should be included in the final answer box.",
            "solution": "The user has provided a problem statement describing a simplified biophysical model of pemphigus vulgaris. The task is to determine the plane of mechanical cleavage in a two-layer epithelial model under specified conditions.\n\n### Step 1: Extract Givens\n\nThe problem provides the following definitions, parameters, and conditions verbatim:\n\n- **Model:** A two-layer stratified squamous epithelium composed of a basal layer and a suprabasal layer.\n- **Interfaces:**\n    1. Basal–suprabasal interface.\n    2. Suprabasal–superficial interface.\n- **Adhesion Molecules:** Desmoglein (Dsg) $3$ and Desmoglein (Dsg) $1$.\n- **Failure Criterion:** Mechanical failure occurs at an interface when the applied shear stress ($T$) exceeds the cohesive adhesion strength ($S$) at that interface.\n- **Adhesion Strength Equations (in arbitrary adhesion units, AAU):**\n    - Basal–suprabasal strength: $S_{bs} = \\alpha_{3}\\,c_{3b}\\,c_{3s} + \\alpha_{1}\\,c_{1b}\\,c_{1s}$\n    - Suprabasal–superficial strength: $S_{ss} = \\beta_{1}\\,c_{1s}^{2} + \\beta_{3}\\,c_{3s}^{2}$\n- **Parameter Values:**\n    - Basal Dsg$3$ concentration: $c_{3b} = 8$\n    - Basal Dsg$1$ concentration: $c_{1b} = 2$\n    - Suprabasal Dsg$3$ concentration: $c_{3s} = 2$\n    - Suprabasal Dsg$1$ concentration: $c_{1s} = 8$\n    - Adhesion coefficients: $\\alpha_{3} = 1$, $\\alpha_{1} = 0.2$, $\\beta_{1} = 1$, $\\beta_{3} = 0.1$.\n- **Applied Stress:** A uniform shear stress $T = 10$ AAU.\n- **Antibody Effect:** Anti-Dsg$3$ antibodies reduce basal–suprabasal adhesion by a fraction of $0.60$.\n- **Post-Antibody Strength:** $S_{bs}^{(\\text{Ab})} = (1 - 0.60)\\,S_{bs}$. The strength $S_{ss}$ is assumed to be unchanged.\n- **Output Convention:**\n    - Code $1$: Cleavage at the basal–suprabasal interface (suprabasal split).\n    - Code $2$: Cleavage at the suprabasal–superficial interface (superficial split).\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem is subjected to validation against the specified criteria.\n\n1.  **Scientifically Grounded:** The problem uses a simplified model, but its foundation is rooted in the established pathology of pemphigus vulgaris, specifically the roles of Dsg$1$ and Dsg$3$ and the effect of autoantibodies. The model does not violate fundamental scientific principles. It is a valid formalization of a biological concept for a quantitative exercise.\n2.  **Well-Posed:** All necessary parameters, equations, and conditions are provided to calculate the adhesion strengths and compare them to the applied stress. The question asks for a unique determination based on these explicit rules, leading to a single, unambiguous answer.\n3.  **Objective:** The problem is stated using precise mathematical definitions and objective numerical values. The criteria for failure and the coding for the answer are unambiguous.\n4.  **No Flaws:** The problem does not exhibit any of the defined flaws such as being incomplete, contradictory, unrealistic (within its own defined units), or ill-posed.\n\n### Step 3: Verdict and Action\n\nThe problem is **valid**. It is a well-posed, self-contained biophysical modeling problem. A complete solution will be provided.\n\n### Solution\n\nThe objective is to determine the cleavage plane by comparing the adhesion strength at two different interfaces with the applied shear stress. The calculation proceeds as follows:\n\nFirst, we calculate the initial adhesion strength of the basal–suprabasal interface, $S_{bs}$, using the provided equation and parameter values.\n$$\nS_{bs} = \\alpha_{3}\\,c_{3b}\\,c_{3s} + \\alpha_{1}\\,c_{1b}\\,c_{1s}\n$$\nSubstituting the given values:\n$$\nS_{bs} = (1)(8)(2) + (0.2)(2)(8) = 16 + 3.2 = 19.2 \\text{ AAU}\n$$\n\nNext, we calculate the adhesion strength of the suprabasal–superficial interface, $S_{ss}$.\n$$\nS_{ss} = \\beta_{1}\\,c_{1s}^{2} + \\beta_{3}\\,c_{3s}^{2}\n$$\nSubstituting the given values:\n$$\nS_{ss} = (1)(8)^{2} + (0.1)(2)^{2} = (1)(64) + (0.1)(4) = 64 + 0.4 = 64.4 \\text{ AAU}\n$$\n\nThe problem states that anti-Dsg$3$ antibodies reduce the basal–suprabasal adhesion strength. The post-antibody strength, $S_{bs}^{(\\text{Ab})}$, is calculated as:\n$$\nS_{bs}^{(\\text{Ab})} = (1 - 0.60) \\, S_{bs}\n$$\nUsing the calculated value of $S_{bs}$:\n$$\nS_{bs}^{(\\text{Ab})} = (0.40) \\times 19.2 = 7.68 \\text{ AAU}\n$$\nThe suprabasal–superficial strength, $S_{ss}$, remains unchanged at $64.4$ AAU.\n\nThe failure criterion is that cleavage occurs where the applied shear stress, $T = 10$ AAU, exceeds the local adhesion strength, $S$. We must check this condition at both interfaces after the antibody action.\n\n1.  **At the basal–suprabasal interface:**\n    We compare the applied stress $T$ with the post-antibody strength $S_{bs}^{(\\text{Ab})}$.\n    Is $T > S_{bs}^{(\\text{Ab})}$?\n    Is $10 > 7.68$? Yes.\n    Therefore, the stress is sufficient to cause failure at the basal–suprabasal interface.\n\n2.  **At the suprabasal–superficial interface:**\n    We compare the applied stress $T$ with the strength $S_{ss}$.\n    Is $T > S_{ss}$?\n    Is $10 > 64.4$? No.\n    Therefore, the stress is insufficient to cause failure at the suprabasal–superficial interface.\n\nSince the applied stress exceeds the adhesion strength only at the basal–suprabasal interface, mechanical failure will occur at this location. This corresponds to a suprabasal split.\n\nAccording to the output convention provided in the problem statement:\n- Code $1$ denotes cleavage at the basal–suprabasal interface.\n- Code $2$ denotes cleavage at the suprabasal–superficial interface.\n\nThe predicted cleavage plane is the basal–suprabasal interface, which corresponds to the integer code $1$.",
            "answer": "$$\\boxed{1}$$"
        },
        {
            "introduction": "A positive diagnostic test does not always mean a patient has the disease; its true meaning depends on the test's accuracy and the disease's prevalence. This fundamental concept in clinical medicine is quantified by the Positive Predictive Value (PPV). This practice  guides you through the calculation of PPV for Direct Immunofluorescence (DIF), a cornerstone test for Pemphigus Vulgaris, using the principles of Bayesian inference to translate raw test data into a meaningful diagnostic probability.",
            "id": "4430043",
            "problem": "Pemphigus vulgaris (PV) is an autoimmune blistering disorder characterized by pathogenic immunoglobulin G (IgG) autoantibodies directed against desmosomal proteins, leading to loss of keratinocyte adhesion. Direct Immunofluorescence (DIF) of perilesional skin is used to detect intercellular deposition of immunoglobulin along the epidermal surfaces and is considered a key diagnostic test. In a dermatopathology clinic, the prevalence (pretest probability) of PV among patients undergoing DIF is $0.05$. The DIF test has a sensitivity of $0.95$ and a specificity of $0.90$, where sensitivity is defined as $P(T^{+}\\,|\\,D)$ (the probability of a positive test given disease) and specificity is defined as $P(T^{-}\\,|\\,\\neg D)$ (the probability of a negative test given no disease). Positive predictive value (PPV) is the posterior probability of disease given a positive test, $P(D\\,|\\,T^{+})$.\n\nUsing only fundamental probability rules and well-tested clinical definitions, determine the positive predictive value of DIF for PV in this clinic. Express your final answer as an exact fraction. Do not use a percentage sign.",
            "solution": "The problem asks for the positive predictive value (PPV) of a diagnostic test, which is the conditional probability that a patient has the disease given a positive test result. We will solve this using Bayes' theorem and the provided definitions and data.\n\n### Step 1: Problem Validation\n\nFirst, we extract the given information verbatim:\n-   Prevalence (pre-test probability) of Pemphigus Vulgaris (PV): $P(D) = 0.05$\n-   Sensitivity of the Direct Immunofluorescence (DIF) test: $P(T^{+}\\,|\\,D) = 0.95$\n-   Specificity of the DIF test: $P(T^{-}\\,|\\,\\neg D) = 0.90$\n-   The quantity to be determined is the Positive Predictive Value (PPV), defined as $P(D\\,|\\,T^{+})$.\n\nWe validate the problem based on these givens.\n1.  **Scientific Grounding**: The problem is grounded in established principles of clinical epidemiology and probability theory. The definitions of prevalence, sensitivity, specificity, and PPV are standard. The description of Pemphigus Vulgaris and the use of DIF testing are factually correct in pathology. The numerical values are plausible for a diagnostic test in a specialized clinical setting.\n2.  **Well-Posedness**: The problem is well-posed. It provides all necessary information to calculate the desired quantity. The objective is clearly stated.\n3.  **Objectivity**: The problem is stated using precise, objective, and formal definitions. There is no subjective or ambiguous language.\n4.  **Consistency and Completeness**: The provided data are self-contained and consistent. There are no missing parameters or contradictory constraints.\n\nThe problem is deemed valid as it is scientifically sound, well-posed, and complete. We may proceed with the solution.\n\n### Step 2: Derivation of the Solution\n\nLet $D$ be the event that a patient has Pemphigus Vulgaris, and $\\neg D$ be the event that the patient does not have the disease. Let $T^{+}$ be the event of a positive test result and $T^{-}$ be the event of a negative test result.\n\nThe quantity we must find is the positive predictive value (PPV), which is the posterior probability $P(D\\,|\\,T^{+})$. According to Bayes' theorem, this is given by:\n$$\nP(D\\,|\\,T^{+}) = \\frac{P(T^{+}\\,|\\,D) P(D)}{P(T^{+})}\n$$\nThe terms in the numerator are given directly in the problem:\n-   The sensitivity, $P(T^{+}\\,|\\,D) = 0.95$.\n-   The prevalence, $P(D) = 0.05$.\n\nThe denominator, $P(T^{+})$, is the total probability of obtaining a positive test result. This can be calculated using the Law of Total Probability, which sums the probabilities of a positive test over all possible disease states (having the disease or not having the disease):\n$$\nP(T^{+}) = P(T^{+} \\cap D) + P(T^{+} \\cap \\neg D)\n$$\nUsing the definition of conditional probability, $P(A \\cap B) = P(A|B)P(B)$, we can rewrite this as:\n$$\nP(T^{+}) = P(T^{+}\\,|\\,D)P(D) + P(T^{+}\\,|\\,\\neg D)P(\\neg D)\n$$\nWe need to determine the two terms on the right-hand side.\n-   The first term, $P(T^{+}\\,|\\,D)P(D)$, consists of the sensitivity and the prevalence, which are given.\n-   The second term, $P(T^{+}\\,|\\,\\neg D)P(\\neg D)$, requires us to find $P(\\neg D)$ and $P(T^{+}\\,|\\,\\neg D)$.\n\nThe probability of not having the disease, $P(\\neg D)$, is the complement of the prevalence:\n$$\nP(\\neg D) = 1 - P(D) = 1 - 0.05 = 0.95\n$$\nThe probability $P(T^{+}\\,|\\,\\neg D)$ is the false positive rate. This is related to the specificity, $P(T^{-}\\,|\\,\\neg D)$, which is the probability of a negative test given no disease. Since a person without the disease can only test positive or negative, these two probabilities must sum to $1$:\n$$\nP(T^{+}\\,|\\,\\neg D) + P(T^{-}\\,|\\,\\neg D) = 1\n$$\nWe are given the specificity $P(T^{-}\\,|\\,\\neg D) = 0.90$. Therefore, the false positive rate is:\n$$\nP(T^{+}\\,|\\,\\neg D) = 1 - P(T^{-}\\,|\\,\\neg D) = 1 - 0.90 = 0.10\n$$\nNow we can calculate the total probability of a positive test, $P(T^{+})$:\n$$\nP(T^{+}) = P(T^{+}\\,|\\,D)P(D) + P(T^{+}\\,|\\,\\neg D)P(\\neg D)\n$$\n$$\nP(T^{+}) = (0.95)(0.05) + (0.10)(0.95)\n$$\nWe can substitute this entire expression for $P(T^{+})$ back into the Bayes' theorem formula for the PPV:\n$$\nP(D\\,|\\,T^{+}) = \\frac{P(T^{+}\\,|\\,D)P(D)}{P(T^{+}\\,|\\,D)P(D) + P(T^{+}\\,|\\,\\neg D)P(\\neg D)}\n$$\nSubstituting the numerical values:\n$$\nP(D\\,|\\,T^{+}) = \\frac{(0.95)(0.05)}{(0.95)(0.05) + (0.10)(0.95)}\n$$\nTo simplify, we can factor out the common term $0.95$ from the denominator:\n$$\nP(D\\,|\\,T^{+}) = \\frac{(0.95)(0.05)}{0.95 \\times (0.05 + 0.10)}\n$$\nCanceling the term $0.95$ from the numerator and denominator yields:\n$$\nP(D\\,|\\,T^{+}) = \\frac{0.05}{0.05 + 0.10} = \\frac{0.05}{0.15}\n$$\nThis fraction simplifies to:\n$$\nP(D\\,|\\,T^{+}) = \\frac{5}{15} = \\frac{1}{3}\n$$\nAlternatively, converting to fractions at the start:\n$P(D) = \\frac{5}{100} = \\frac{1}{20}$\n$P(\\neg D) = 1 - \\frac{1}{20} = \\frac{19}{20}$\n$P(T^{+}\\,|\\,D) = \\frac{95}{100} = \\frac{19}{20}$\n$P(T^{-}\\,|\\,\\neg D) = \\frac{90}{100} = \\frac{9}{10}$, so $P(T^{+}\\,|\\,\\neg D) = 1 - \\frac{9}{10} = \\frac{1}{10}$\n\nPPV = $P(D\\,|\\,T^{+}) = \\frac{(\\frac{19}{20})(\\frac{1}{20})}{(\\frac{19}{20})(\\frac{1}{20}) + (\\frac{1}{10})(\\frac{19}{20})}$\n$P(D\\,|\\,T^{+}) = \\frac{\\frac{19}{400}}{\\frac{19}{400} + \\frac{19}{200}} = \\frac{\\frac{19}{400}}{\\frac{19}{400} + \\frac{38}{400}} = \\frac{\\frac{19}{400}}{\\frac{57}{400}} = \\frac{19}{57} = \\frac{1}{3}$.\nThe positive predictive value of the DIF test for PV in this clinic is $\\frac{1}{3}$.",
            "answer": "$$\\boxed{\\frac{1}{3}}$$"
        },
        {
            "introduction": "Effective treatment of autoimmune diseases like pemphigus vulgaris requires understanding the dynamics of both the immune system and the therapeutic agent. This problem  delves into the pharmacodynamics of rituximab, a modern biologic therapy, by using a mathematical model to describe its effect on pathogenic autoantibody levels. By solving a differential equation that captures both the depletion of antibody-secreting cells and the natural clearance of antibodies, you will quantify the expected therapeutic response over time, bridging the gap between molecular action and clinical outcome.",
            "id": "4429974",
            "problem": "A patient with pemphigus vulgaris has pathogenic Immunoglobulin G (IgG) autoantibodies targeting desmogleins, causing suprabasal acantholysis. In the absence of therapy, the serum autoantibody concentration is maintained by antibody-secreting cells (short-lived plasma cells) derived from B cells. After administration of rituximab, an anti-CD20 monoclonal antibody (mAb), the population of antibody-secreting cells is assumed to decline exponentially according to the well-tested model of first-order loss of a population, $N(t) = N_{0}\\exp(-\\lambda t),$ where $N(t)$ is the number of antibody-secreting cells at time $t$ (in days), $N_{0}$ is the pre-therapy number, and $\\lambda$ is the depletion rate constant induced by therapy.\n\nAssume:\n- Each secreting cell produces autoantibody at a constant rate $s$ (moles per cell per day), so the source term is proportional to $N(t)$.\n- Serum autoantibody is removed by first-order catabolism with rate constant $\\mu$ (per day), consistent with IgG elimination kinetics.\n- Before therapy, the system is at steady state with $N(t) = N_{0}$ constant and $dA/dt = 0$, where $A(t)$ is the serum autoantibody concentration.\n\nStarting at $t = 0$ (therapy initiation), the governing equation for autoantibody concentration becomes $\\frac{dA}{dt} = sN(t) - \\mu A(t), \\quad A(0) = \\frac{sN_{0}}{\\mu}.$\n\nUsing the above, compute the expected reduction in pathogenic autoantibody activity at time $t = 28$ days, defined as the fractional decrease $$R(t) = 1 - \\frac{A(t)}{A(0)},$$ under the parameter values $$\\mu = \\frac{\\ln(2)}{21} \\text{ per day}, \\quad \\lambda = \\frac{\\ln(2)}{7} \\text{ per day}.$$\n\nExpress your final answer as a decimal fraction without a percentage sign, and round your answer to four significant figures.",
            "solution": "The problem requires the calculation of the fractional reduction in serum autoantibody concentration at a specific time, based on a given pharmacokinetic model.\n\nFirst, we must solve the governing differential equation for the serum autoantibody concentration, $A(t)$. The problem statement provides the equation and the initial condition:\n$$\n\\frac{dA}{dt} = sN(t) - \\mu A(t), \\quad A(0) = \\frac{sN_0}{\\mu}\n$$\nThe population of antibody-secreting cells, $N(t)$, is given by $N(t) = N_0 \\exp(-\\lambda t)$. Substituting this into the differential equation gives:\n$$\n\\frac{dA}{dt} = s N_0 \\exp(-\\lambda t) - \\mu A(t)\n$$\nThis can be rewritten in the standard form for a first-order linear ordinary differential equation:\n$$\n\\frac{dA}{dt} + \\mu A(t) = sN_0 \\exp(-\\lambda t)\n$$\nThis equation can be solved using an integrating factor, $I(t)$. The integrating factor is given by:\n$$\nI(t) = \\exp\\left(\\int \\mu \\, dt\\right) = \\exp(\\mu t)\n$$\nMultiplying the differential equation by $I(t)$:\n$$\n\\exp(\\mu t) \\frac{dA}{dt} + \\mu \\exp(\\mu t) A(t) = sN_0 \\exp(-\\lambda t) \\exp(\\mu t)\n$$\nThe left side of the equation is the derivative of the product $A(t)I(t)$:\n$$\n\\frac{d}{dt} \\left[ A(t) \\exp(\\mu t) \\right] = sN_0 \\exp((\\mu - \\lambda)t)\n$$\nTo find $A(t)$, we integrate both sides with respect to $t$. The problem specifies that $\\mu = \\frac{\\ln(2)}{21}$ and $\\lambda = \\frac{\\ln(2)}{7}$, so $\\mu \\neq \\lambda$.\n$$\nA(t) \\exp(\\mu t) = \\int sN_0 \\exp((\\mu - \\lambda)t) \\, dt\n$$\n$$\nA(t) \\exp(\\mu t) = \\frac{sN_0}{\\mu - \\lambda} \\exp((\\mu - \\lambda)t) + C\n$$\nwhere $C$ is the constant of integration. Solving for $A(t)$:\n$$\nA(t) = \\frac{sN_0}{\\mu - \\lambda} \\exp(-\\lambda t) + C \\exp(-\\mu t)\n$$\nTo determine the constant $C$, we apply the initial condition $A(0) = \\frac{sN_0}{\\mu}$. At $t=0$:\n$$\nA(0) = \\frac{sN_0}{\\mu - \\lambda} \\exp(0) + C \\exp(0)\n$$\n$$\n\\frac{sN_0}{\\mu} = \\frac{sN_0}{\\mu - \\lambda} + C\n$$\nSolving for $C$:\n$$\nC = \\frac{sN_0}{\\mu} - \\frac{sN_0}{\\mu - \\lambda} = sN_0 \\left( \\frac{1}{\\mu} - \\frac{1}{\\mu - \\lambda} \\right) = sN_0 \\left( \\frac{(\\mu - \\lambda) - \\mu}{\\mu(\\mu - \\lambda)} \\right) = -\\frac{sN_0 \\lambda}{\\mu(\\mu - \\lambda)}\n$$\nSubstituting $C$ back into the solution for $A(t)$:\n$$\nA(t) = \\frac{sN_0}{\\mu - \\lambda} \\exp(-\\lambda t) - \\frac{sN_0 \\lambda}{\\mu(\\mu - \\lambda)} \\exp(-\\mu t)\n$$\nThe problem asks for the fractional decrease $R(t) = 1 - \\frac{A(t)}{A(0)}$. We first compute the ratio $\\frac{A(t)}{A(0)}$:\n$$\n\\frac{A(t)}{A(0)} = \\frac{\\frac{sN_0}{\\mu - \\lambda} \\exp(-\\lambda t) - \\frac{sN_0 \\lambda}{\\mu(\\mu - \\lambda)} \\exp(-\\mu t)}{\\frac{sN_0}{\\mu}}\n$$\nThe term $sN_0$ cancels out:\n$$\n\\frac{A(t)}{A(0)} = \\frac{\\mu}{\\mu - \\lambda} \\exp(-\\lambda t) - \\frac{\\lambda}{\\mu - \\lambda} \\exp(-\\mu t) = \\frac{1}{\\mu - \\lambda} \\left( \\mu \\exp(-\\lambda t) - \\lambda \\exp(-\\mu t) \\right)\n$$\nIt is convenient to rewrite this as:\n$$\n\\frac{A(t)}{A(0)} = \\frac{1}{\\lambda - \\mu} \\left( \\lambda \\exp(-\\mu t) - \\mu \\exp(-\\lambda t) \\right)\n$$\nNow, we substitute the given parameter values:\n$$\n\\mu = \\frac{\\ln(2)}{21} \\text{ per day}\n$$\n$$\n\\lambda = \\frac{\\ln(2)}{7} \\text{ per day}\n$$\nWe note that $\\lambda = 3\\mu$. Substituting this relationship into the expression for the ratio simplifies it:\n$$\n\\frac{A(t)}{A(0)} = \\frac{1}{3\\mu - \\mu} \\left( 3\\mu \\exp(-\\mu t) - \\mu \\exp(-3\\mu t) \\right) = \\frac{1}{2\\mu} \\left( \\mu(3 \\exp(-\\mu t) - \\exp(-3\\mu t)) \\right)\n$$\n$$\n\\frac{A(t)}{A(0)} = \\frac{1}{2} \\left( 3 \\exp(-\\mu t) - \\exp(-3\\mu t) \\right)\n$$\nWe need to evaluate this expression at $t=28$ days. First, let's calculate the value of the exponent $\\mu t$:\n$$\n\\mu t = \\left(\\frac{\\ln(2)}{21}\\right) \\times 28 = \\frac{4}{3} \\ln(2) = \\ln(2^{4/3})\n$$\nThen, the exponential terms are:\n$$\n\\exp(-\\mu t) = \\exp(-\\ln(2^{4/3})) = \\exp(\\ln(2^{-4/3})) = 2^{-4/3}\n$$\n$$\n\\exp(-3\\mu t) = \\exp(-3 \\ln(2^{4/3})) = \\exp(-\\ln((2^{4/3})^3)) = \\exp(-\\ln(2^4)) = 2^{-4}\n$$\nSubstituting these into the equation for the ratio:\n$$\n\\frac{A(28)}{A(0)} = \\frac{1}{2} \\left( 3 \\cdot 2^{-4/3} - 2^{-4} \\right) = \\frac{3}{2 \\cdot 2^{4/3}} - \\frac{1}{2 \\cdot 2^4} = \\frac{3}{2^{7/3}} - \\frac{1}{32}\n$$\nNow we compute the numerical value of this expression:\n$$\n2^{7/3} \\approx 5.039684\n$$\n$$\n\\frac{A(28)}{A(0)} \\approx \\frac{3}{5.039684} - \\frac{1}{32} \\approx 0.595285 - 0.03125 = 0.564035\n$$\nThe reduction $R(t)$ is defined as $R(t) = 1 - \\frac{A(t)}{A(0)}$. At $t=28$ days:\n$$\nR(28) = 1 - \\frac{A(28)}{A(0)} \\approx 1 - 0.564035 = 0.435965\n$$\nThe problem requires the answer to be rounded to four significant figures. Rounding $0.435965$ to four significant figures gives $0.4360$.",
            "answer": "$$\\boxed{0.4360}$$"
        }
    ]
}